<?xml version="1.0" encoding="UTF-8"?>
<fig id="F0002" orientation="portrait" position="float">
 <label>Figure 2.</label>
 <caption>
  <p>(A) Appearance of the SNEDDS preconcentrate (in glass tubes) and SNEDDS after aqueous dilution with water (in glass beaker) that were developed with black seed oil (BSO) and soybean oil (SBO) for the model drugs, sitagliptin and dapagliflozin, as combined dosage form. (B) The F1-SNEDDS combined dosage form filled into hard gelatin capsule and the appearance of the diluted SNEDDS (10 mg anhydrous formulation was diluted in 10 mL water [1 in 1000 w/v]) and (C) Formation of nanodroplets/micelles from F1-SNEDDS in presence of bile salt: phospholipid and pancreatic lipase during lipid digestion in the small intestine.</p>
 </caption>
 <graphic content-type="color" xlink:href="IDRD_A_1859001_F0002_C" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
